Clinical Trial Update: A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) [Phase 1]

View source ↗

Summary

Phase 1 trial update of belzutifan (PT2977, MK-6482) in patients with advanced solid tumors; study status is Phase 1 and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Glioblastoma
• Renal Cell Carcinoma

Drugs mentioned

• Welireg (Belzutifan) (belzutifan)

Snippet

Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Advanced Solid Tumors, Solid Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING